The effects of O6-methyl guanine DNA-methyl transferase promotor methylation and CpG1, CpG2, CpG3 and CpG4 methylation on treatment response and their prognostic significance in patients with glioblastoma

Autor:	Yakut Erdem, Aynur Aytekin, Oğuz Yildiz, Sadik Özöner, Hilal Akalin, Munis Dundar, Dicle Aslan, Özlem Canöz
Jazyk:	angličtina
Rok vydání:	2020
Předmět:	0301 basic medicine Oncology medicine.medical_specialty medicine.medical_treatment QH426-470 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Genetics o6-methyl guanine methyl transferase (mgmt) methylation Genetics (clinical) Temozolomide business.industry glioblastoma (gb) radiotherapy (rt) Methylation Odds ratio Radiation therapy 030104 developmental biology CpG site 030220 oncology & carcinogenesis Concomitant Biomarker (medicine) Original Article business Adjuvant medicine.drug
Zdroj:	Balkan Journal of Medical Genetics, Vol 23, Iss 1, Pp 33-41 (2020) Balkan Journal of Medical Genetics : BJMG
ISSN:	1311-0160
Popis:	This retrospective study examined the prognostic significance and treatment effect of promoter methylation of O6- methyl guanine methyl transferase (MGMT) and meth-ylation of CpG 1, CpG2, CpG3 and CpG4 in glioblastoma (GB) patients received postoperative radiotherapy (PORT), with or without adjuvant temozolomide (TMZ). One hundred patients with GB who received PORT with concomitant TMZ plus adjuvant TMZ or PORT alone, were included. The MGMT promoter methylation of CpG1, CpG2, CpG3 and CpG4 islands were examined. Overall, MGMT-methylation emerged as a significant prognostic factor for better overall survival (OS) and progression-free survival (PFS) [odds ratio (OR): 0.609, 95% confidence interval (95% CI): 0.395-0.939, p = 0.02; OR: 0.662,95% CI: 0.430-1019, p = 0.5, respectively]. The methylation of each CpG1, CpG2, CpG3 and CpG4 islands was found to have no significant effects on OS and the methylation of each CpGl, CpG2 and CpG4 islands had no significant effect on PFS (p p = 0.04). In the group that only received radiotherapy (RT), CpG1 and CpC3 methylations were found to have a positive prognostic significance in terms of PFS (OR: 266, 95% CI: 1.05-6.75, p -0.03 for CpG1; OR: 2.4, 95% CI: 1.01-5.92, p = 0.04 for CpG3). The MGMT promoter methylation represents an important biomarker for predicting response to therapy. Individual islands, particularly CpG3, deserves further investigation as a prognostic marker. Further studies need to be done with larger sample sizes to clarify the results.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::baa3be81e075fc506eade38c0cc6a320 https://doaj.org/article/e2ab5a1460de414884a26eb0001403ce Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.